Having 60 starters in the trial is a reasonable number, to get an indication of its effectiveness especially with information gained from the bio markers. The delay and possible additional research may enhance a positive result. As a guess this article was formulated by Kempler not David Stamler because of the lack, of additional information shareholders would appreciate.
Ann: Expanded ATH434 Phase 2 Clinical Development Program, page-10
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $2.733K | 832.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 45274833 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 126718541 | 16 |
View Market Depth
| Last trade - 15.57pm 09/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |